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Abstract: The glycosylphosphatidylinositol-linked GDNF (glial cell derived neurotrophic factor)
receptor alpha (GFRA), a coreceptor that recognizes the GDNF family of ligands, has a crucial role
in the development and maintenance of the nervous system. Of the four identified GFRA isoforms,
GFRA1 specifically recognizes GDNF and is involved in the regulation of proliferation, differentiation,
and migration of neuronal cells. GFRA1 has also been implicated in cancer cell progression and
metastasis. Recent findings show that GFRA1 can contribute to the development of chemoresistance
in osteosarcoma. GFRA1 expression was induced following treatment of osteosarcoma cells with
the popular anticancer drug, cisplatin and induction of GFRA1 expression significantly suppressed
apoptosis mediated by cisplatin in osteosarcoma cells. GFRA1 expression promotes autophagy
by activating the SRC-AMPK signaling axis following cisplatin treatment, resulting in enhanced
osteosarcoma cell survival. GFRA1-induced autophagy promoted tumor growth in mouse xenograft
models, suggesting a novel function of GFRA1 in osteosarcoma chemoresistance.
Keywords: GFRA1; osteosarcoma; chemoresistance; GDNF; RET

1. Introduction
Neurotrophic factors (NTFs) are a family of peptides or small proteins including neurotrophins,
neurokines and the glial cell line-derived neurotrophic factor (GDNF) family of ligands, or GFLs.
NTFs are known as key regulators of neuronal ontogeny, neuronal survival, differentiation, migration,
synapse plasticity and function in both the developing and adult nervous systems. They exert their
signaling through kinases such as receptor tyrosine kinases (RTKs). Since it was characterized in 1993,
the GDNF subfamily of NTFs has been well-studied. The GDNF family consists of GDNF, Neurturin
(NRTN), Artemin (ARTN), and Persephin (PSPN) which are also members of the transforming
growth factor-beta superfamily [1–7]. GDNF was isolated from a glial cell line related to the survival
of midbrain dopaminergic neurons, and its loss is associated with neurodegenerative diseases
like Parkinson’s disease [8]. Mainly, GDNF affects many types of neurons in both the peripheral
(sympathetic, parasympathetic, sensory and enteric neurons) and central nervous systems (midbrain
dopamine neurons and motoneurons) [9,10]. RET (rearranged during transformation) receptor
tyrosine kinase was the first RTK to be identified as a GFL co-receptor in 1996. RET is a single
transmembrane-spanning RTK that is essential to vertebrate development of the central and peripheral
nervous systems, kidney and Peyer’s patch organogenesis, and spermatogenesis [11]. Its mutated
form is found in endocrine human cancers and cases of Hirschsprung disease [12]. However, it was
thought that RET cannot bind directly to GDNF until another GFL co-receptor, GDNF receptor alpha 1
(GFRA1), was identified. Interestingly, the ligand-binding specificity of GFLs is determined by GFRA
proteins that have unique high binding affinities for each GFL. So far, three glycosylphosphatidyl
inositol (GPI)-anchored co-receptors related to GFRA1 have been found: GFRA2, GFRA3 and GFRA4
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(Figure 1) [9]. As shown in Figure 1, GFRA1 directly interacts with GDNF and alternatively, it can
bind ARTN or NRTN; GFRA2 binds with NRTN; GFRA3 interacts with ARTN; and GFRA4 is the
preferential co-receptor for PSPN. Although it has been shown that GFLs bind with their co-receptors,
the mechanisms by which these interactions occur still have not been elucidated. As described in
Figure 2, there are currently two hypothetic modes of interaction between GDNF and RET. In the first
mode, GFLs make dimers and form a high-affinity complex with one of four GFRAs. Each GFL-GFRA
homodimer complex recruits c-RET to a lipid raft, a platform containing receptors and messenger
proteins for signal transduction, which triggers autophosphorylation of specific tyrosine residues
in the kinase domains of RET and intracellular signaling [9]. In the second mode, a pre-associated
complex between GFRA and RET could form the binding site for the GFLs [13]. The physiological
roles and regulatory mechanism of GDNF has been relatively well studied as opposed to ARTN,
NRTN and PSPN which have rarely been reported. As shown in Figure 3, once GDNF/GFRA1/RET
makes a complex, it activates various signaling pathways, such as RAS/MAPK, PI3K/Akt and PLCγ
pathway, which contribute to cell proliferation, adhesion, migration, differentiation and survival
and which contribute to the pathogenesis of both cancer and neuronal disease [14,15]. However,
in a RET-independent pathway, GPI-anchored GFRA1 is localized to lipid rafts in the plasma
membrane and then, the GDNF-GFRA1 complex triggers a Src-dependent signaling pathway, leading
to neuronal differentiation and survival [13]. Once RET was identified, additional attempts to find
other signal-transducing GDNF receptors failed for several years until the Paratcha research group
discovered neural cell adhesion molecule (NCAM) as an alternative signaling co-receptor for GFLs [16].
Indeed, in cultured Schwann cells and cortical neurons, GDNF/GFRA1/p140NCAM complex activates
the cytoplasmic protein tyrosine kinase Fyn and FAK, two downstream mediators of p140NCAM [16].

Figure 1. The interaction of glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs)
with their receptors. Four homodimeric GFLs (GDNF, NRTN, ARTN, and PSPN) recognize their
corresponding GDNF family receptor α (GFRα/GFRA1-4). GDNF specifically binds to GFRA1, NRTN
to GFRA2, ARTN to GFRA3, and PSPN to GFRA4. Dotted arrow indicates cross-interaction of
GFLs with GFRA which has been observed. Binding of GFL with GFRA activates protein tyrosine
kinase RET. Neural cell adhesion molecule (NCAM) has been identified as an alternative signaling
receptor for GFLs. RET also has been known as the representative receptor tyrosine kinases (RTKs)
for these neurotrophic factor receptors. Activation of RET or NCAM via the GFL/GFRA complex is
involved in various physiological functions, such as neuronal cell growth, differentiation, migration,
and osteosarcoma chemoresistance via autophagy. Gray-colored area of the membrane indicates lipid
raft. NRTN, neurturin; ARTN, artemin; PSPN, persephin.
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Figure 2. Two hypothetical modes of RET interaction/stimulation by GFL/GFRA. The extracellular
domain of RET tyrosine kinase binds with GFL/GFRA which is linked to the plasma membrane via
a glycosyl phosphatidylinositol (GPI) anchor. The interaction of RET with GFL/GFRA leads to the
phosphorylation of tyrosine residues located in intracellular domain of RET and activates downstream
signaling pathways. (A) GFL dimer binds to the GPI-anchored GFRA in lipid rafts and recruits RET;
(B) GFRA without ligand forms a complex with RET that can serve as a receptor for GFL dimer.

Figure 3. Cont.
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Figure 3. Schematic presentation of regulatory mechanisms of GFL-GFRA1 signaling. (A) RET is
recruited to the lipid microdomain (or lipid rafts) by GPI-anchored GFRA1 (left side, cis-signaling)
and by soluble GFRA1 (right side, sGFRA1, trans-signaling) released from plasma membrane. During
cis-signaling, GFRA1 is anchored to lipid rafts by GPI, allowing GFLs to bind to GFRA1 to transduce
their signals to co-receptor RET which can then activate downstream targets like Src kinase, PLCγ,
or PI3K/AKT. Trans-signaling occurs when the GDNF/sGFRA1 complex binds to RET on another
peripheral neuron which does not express GFRA1. GDNF/sGFRA1/RET can then transduce their
signal to downstream targets such as PI3K/AKT and PLCγ/Cdk5, resulting in neuronal survival
and neurite outgrowth; (B) In the absence of GFLs, short-range signaling by homophilic interactions
between p140NCAM can be disrupted by the presence of GFRA, resulting in the inhibition of cell
adhesion, or extracellular signaling crosstalk (left side). In the presence GFLs, the association of
membrane-bound GFRA with p140NCAM results in the activation of the Fyn-FAK-MAPK signaling
pathway (right side); (C) Ligand-induced cell adhesion; (D) Recycling of GDNF/GFRA1/RET
complex by SorLA. SorLA/GFRA1-mediated GDNF uptake occurs by RET-independent endocytosis.
SorLA/GFRA1 complex directs GDNF to lysosome. SorLA/GFRA1-mediated RET endocytosis is
independent of GDNF.

Until now, GDNF/GFRA1 signaling has been regarded as an emerging potential therapeutic
target in neuronal disease. However, recent studies have reported that GFRA1 also is implicated
in cancer signaling. Moreover, our recent research with osteosarcoma demonstrated that GFRA1
promotes cell survival against the well-known anticancer agent cisplatin by promoting autophagy,
a novel resistance mechanism against chemotherapy. In this review, we summarize the current studies
and focus on the physiological role of GFRA1 in chemoresistance.
2. Regulatory Mechanisms of GDNF/GFRA1 Signaling
Since GDNF was initially identified as a survival factor for midbrain dopaminergic neurons,
it has been investigated in regards to various neural developmental processes, including kidney
morphogenesis and spermatogenesis [11,17–19]. GDNF signaling is much more complex than initially
expected due to the complexity of interaction among GDNF and its co-receptors. This section will
briefly summarize the regulatory mechanisms for GDNF signaling and its receptors.
2.1. GFRA1-RET Signaling
GFRA1-RET signal transduction can be divided into two pathways: cis-signaling and
trans-signaling. As described in Figure 3A, cis-signaling is an action mechanism that occurs on the
same membrane. GPI-anchored GFRA1 is localized to a specialized plasma membrane microdomain,
or lipid rafts. Once GFLs bind to GFRA1, it transfers its signals to co-receptor RET which can
activate downstream targets like Src kinase, RAS/MAPK, PLCγ, or PI3K/AKT, resulting in cell
proliferation, migration and survival in cancer and neuronal cells [20]. Trans-signaling is referred to as
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non-cell-autonomous action at a distance (Figure 3A). Soluble GFRA1 (sGFRA1) is constitutively
released by phospholipases and shed from the cell surface. sGFRA1 binds to GDNF with high
affinity and is stably-floated. Once in complex, sGFRA1/GDNF promotes neuronal survival and
neurite outgrowth by binding with RET on the membrane of GFRA1-deficient RET-expressing
cells [21]. The discovery of sGFRA1 in both Schwann cells and injured sciatic nerves opens the
possibility that lesioned peripheral nerves can be readily recovered through GDNF/sGFRA1/Cdk5
axis-axon-guidance activities provided by the adjacent Schwann cells [21,22].
2.2. GFRA1-NCAM Signaling
Neural cell adhesion molecule (NCAM) is a hemophilic binding glycoprotein expressed on the
surface of neurons, glia and skeletal muscle [23–28]. It also has been found to be expressed in the
immune cells including natural killer cells, gamma delta T cells, activated CD8+ T cells and dendritic
cells [29–31]. Alternative mRNA splicing of the NCAM gene produces three isoforms: p120, p140,
p180 [32]. Studies have shown that NCAM plays critical roles in cell-cell adhesion, neurite outgrowth,
neuronal survival, synapse formation and synaptic plasticity [16,33,34]. Interestingly, the presence of
GDNF/GFRA1 is required for NCAM-mediated neuronal signal transduction. Given that NCAM is
an alternative signaling receptor for GFLs, recent investigations of NCAM have been focused on the
clarification of novel mechanisms that could be applied towards successful clinical trials using GDNF
or GFRA1 [16]. Homophilic binding occurs between NCAM molecules on opposing surface (trans-)
and on same surface (cis-). As shown in Figure 3B, dimerization of NCAM functions in neurite growth
via FAK and Fyn, two mediators downstream of NCAM [16]. As a negative regulator, GFRA1 can
inhibit the interaction between NCAM molecules in the absence of GDNF (Short-range). However,
once GDNF is infused from outside, GFRA1 promotes extracellular crosstalk by helping GDNF to
bind with NCAM (Long-range). As will be described in the next regulatory mechanism, in vivo the
NCAM-deficient model shows abnormality of size in the olfactory bulb (OB) caused by defects in
neuronal cell migration in the rostral migratory stream (RMS). Interestingly, overexpression of GDNF
or NCAM in RET-deficient mice recover the size of OB. The results indicate that RET-independent
GDNF signaling via NCAM can play a role in the migration and guidance of neuroblasts and in the
development of the RMS-OB [16].
2.3. GDNF-GFRA1 Signaling: Ligand-Induced Cell Adhesion
Unlike other cell-adhesion molecules (CAMs) trans-interacting among cells, GFRA1-mediated cell
adhesion requires the presence of GDNF. As such, GFRA1 is sometimes referred to as a ligand-induced
cell-adhesion molecule (LICAM). In this case, GPI-anchored GFRA1 and soluble GDNF form a complex
that induces cell adhesion working in a similar status (Figure 3C). Although the means by which
GDNF-induced trans-homophilic interactions occur are not clear, GFRA1-knockout mutants indicate
that GDNF-induced cell adhesion is required for the linkage between GFRA1 and GDNF. Thus,
this mechanism plays a role in the development of the nervous system by permitting the interaction
between neuronal and glial cells [35].
2.4. GFRA1-SorLA Signaling
Until now, the mechanism of GDNF downregulation has not been studied, unlike degradation by
ubiquitination. Recently, the Glerup group demonstrated that SorLA (sorting protein-related receptor)
binds to GFRA1 or RET, which induces GDNF/GFRA1 recycling (Figure 3D). In this process, SorLA
plays a role as a co-receptor of GDNF. Indeed, SorLA has much higher affinity for GDNF/GFRA1 than
RET for endocytosis, but it does not degrade GFRA1. While SorLA mediates GFRA1 recycling through
the endosome, GDNF is transferred to the lysosome for degradation. In SorLA-deficient mice, the level
of GDNF protein is elevated with abnormal GDNF activity [36]. The findings showed a novel role for
GFRA1 in that it is involved in the degradation of GDNF through its binding to SorLA, which induces
GDNF/GFRA1 recycling through endocytosis.
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3. Physiological Roles of GFRA1 in Disease
GDNF was purified and characterized as a survival factor of the embryonic dopaminergic
neurons of the midbrain, which degenerate in Parkinson’s disease [8]. In addition, it works as a
potent neurotrophic factor for spinal motor neurons [37]. Thanks to its robust role in the neuron,
GDNF is regarded as a highly promising therapeutic agent for the treatment of neurodegenerative
disease. Although phase I clinical trials with Parkinson’s patients using direct infusions into the
putamen were very effective, phase II studies resulted in conflicting outcomes [38,39]. As previously
mentioned, GFRA1 is a GPI-anchored cell surface receptor for GDNF, NRTN and ARTN. The effect
of GFRA1 signaling can be determined by a variety of interactions and its expression levels. In other
words, its aberrant expression or mutation of co-receptors may cause the abnormalities in neuronal
survival and differentiation. Thus, the key to combating GFL/GFRA1-related disease is to understand
the widespread expression of GFRA1 proteins in various tissues in combination with and without
RET signaling.
In certain types of neurons, the RET-associated GFL/GFRA1 complex activates several
intracellular signaling cascades, which regulate cell survival, differentiation, proliferation, migration,
chemotaxis, branching morphogenesis, neurite outgrowth and synaptic plasticity. Our previous
report demonstrated that GFRA1 overexpression is associated with advanced pancreatic cancer [40].
APE1 (apurinic/apyrimidinic endodeoxynuclease 1)-induced GFRA1 protein forms a complex
with RET through a lipid raft, which stimulates cell proliferation and migration in pancreatic
cancer. Additionally, GFRA1 expression increases neurite outgrowth and survival against β-amyloid
peptide accumulation in neuronal cell lines [41]. In other words, loss of GFRA1 is implicated in
neurodegenerative disease, such as Alzheimer’s (AD) and Parkinson’s disease (PD) [41]. Mutations
in RET are common in Hirschsprung’s disease which is characterized by the absence of neuronal
ganglia in various parts of the colon, leading to severe constipation and intestinal obstruction
during childhood [42]. Although a GFRA1 mutation has not been found in Hirschsprung’s patients,
Hirschsprung’s disease has been observed in heterozygous GDNF+/− mice [43]. However, mutated
GDNF does not reduce the activation of RET [44]. Interestingly, mutated NRTN has also been shown
to be involved in this disease. Collectively, the results imply that mutation in GDNF, NRTN or RET
reduce the affinity for GFRA1 interaction, resulting in Hirschsprung’s disease [43,45,46].
In the RET-independent pathway, there are two possibilities for GFRA signaling: (1) use
of other receptor systems (NCAM, SorLA, Syndecan, MET, ErbB4) or (2) direct GFL/GFRA1
signaling through cytosolic tyrosine kinases, like Src [47–49]. For example, GDNF/GFRA1 signaling
via NCAM contributes to the regulation/modulation of the process of neuronal development,
including proliferation, neuronal fate specification, differentiation, neurite outgrowth, and synapse
formation [50–53]. In contrast, GFRA1 can act to antagonize NCAM-mediated cell adhesion, which
directly acts between GFRA1 and the 4th domain of NCAM [54]. Independently of NCAM, GFRA1
can also act as a cell adhesion molecule by itself, which is termed ligand-mediated cell adhesion [35].
Syndecan-3 is implicated in GDNF signaling through its heparan sulfate chains [47]. In GABAergic
interneurons of the medial ganglionic eminence (MGE), GDNF signaling can transfer via MET or
ErbB4 [48,49].
As mentioned above, most studies of GDNF/GFRA1 signaling are related to neurodegenerative
(Parkinson’s disease and Alzheimer’s disease) and neuropsychiatric diseases (addiction, bipolar
disorder, obsessive compulsive disorder, depression, anxiety, autism, schizophrenia, and attention
deficit hyperactivity disorder). Moreover, recent therapeutic approaches for GDNF/GFRA1 signaling
are intended to investigate how GDNF is infused to target cells or to find what can interact with
GFRA1 [55]. In the brain dopamine system, GDNF-based therapy is rising in treatment of Parkinson’s
disease (PD) which is caused by cell death in the substania nigra pars compata (SNpc) of the midbrain,
due to loss of dopamine [56]. SNpc contains about 10,000–15,000 dopaminergic neurons which express
GFRA1 and RET [57]. Recent PD models show the symptom after more than 50% of striatal dopamine
levels and 30–40% of SNpc neurons are lost [58]. Additionally, rodent models of PD demonstrate
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that the axonal trees of the remaining axons can re-innervate the striatal areas left vacant by the
degenerating dopaminergic neurons to inhibit or reverse the progression of PD via GDNF delivery [58].
Moreover, the recent rodent models for ectopic overexpression of GDNF or GFRA1 in the forebrain of
mice using a neuron-specific CAMKII promoter demonstrates that endogenous GDNF is essentially
required for midbrain dopaminergic neuron development of maintenance [59,60]. Subsequently, the
successes and draw-backs of GDNF-based therapies in PD need a physiological understanding of
GDNF/GFRA1 signaling in vivo.
GDNF and its receptors have been shown to be concentrated within the midbrain. However, they
are often observed in many other brain regions in the CNS. Recent studies show that GDNF and its
two receptors (GFRA1 and NCAM) are expressed by hippocampal neurons during embryonic and
early postnatal stages [22,35,61]. In other words, GFRA1 functions as a ligand-induced cell adhesion
molecule at synaptic sites, which promotes cell-to-cell interaction for communication among cells. Once
abnormal expression of GFRA1 or NCACM decreases presynaptic maturation during hippocampal
synaptogenesis, neuropsychiatric disorders can occur [22,61]. In GABAergic neurons, GFRA1 signaling
plays a critical role in the development of the olfactory system. Although GFRA1 itself was not
expressed by matured GABAergic neurons in the olfactory bulb (OB), all major classes of GABAergic
interneurons are reduced or deficient by non-cell-autonomous functions of GFRA1 in other factors
of the olfactory system [62]. In addition, the upregulation of GDNF and GFRA1 has been reported
in stroke (ischemia) and epilepsy (seizure disorder) [63,64]. In contrast, GDNF levels were found
to be decreased in Alzheimer’s disease (AD), leading to progressive loss of cognitive function and
dementia [65]. In fact, despite occurring in more than 10% of people after the age of 65, AD diagnosis
in early stages is still difficult. Importantly, a recent study showed that GDNF was found as one of 18
signaling proteins identified in blood from 250 AD patients [66]. As mentioned earlier, recent AD studies
suggest that GDNF increases the survival of cells by promoting the release of β-amyloid peptide from
neuron-like cells, without increased expression of amyloid protein precursor (APP) or secretase [40,65].
Intriguingly, recent studies of neuropsychiatric disorders have reported that increased protein levels of
GDNF or its polymorphism were observed in addiction, bipolar disorder, obsessive compulsive disorder,
autism, schizophrenia, and attention deficit hyperactivity disorder [67–71]. In contrast, the protein
levels of GDNF and its receptor GFRA1 were reduced in depression. In particular, downregulation of
GFRA1a was associated with increased expression of microRNAs. Further studies showed that miR-511,
which targets long 30 untranslated region-containing transcripts coding for GFRA1a, repressed GFRA1a
expression in human neural progenitor cells without altering GFRA1b expression, suggesting that
microRNAs are involved in the modulation of GDNF/GFRA1 signaling [72].
Taken together, these findings demonstrate that clarification of the emerging roles of
GDNF/GFRA1 signaling in CNS and PNS is essential to the development of biomarkers to accurately
diagnose and drugs to treat these neuronal diseases.
4. GFRA1 in Cancer
Given the function of GFRA1 in neuronal development, GFRA1 has been studied with eyes on
the emerging therapeutic treatment in neuronal disease, especially Parkinson’s disease. However,
recent evidence suggests that GFRA1 is robustly involved in cancer progression [73]. Indeed, aberrant
GDNF or GFRA1 expression has been often found in various cancer cells including those of the
pancreas, skin and breast, as well is in osteosarcoma (Table 1). Recent studies provide evidence
that GFRA1 is implicated in tumorigenesis and cancer progression. One research group showed
that GFRA1 and RET are overexpressed in estrogen receptor-positive (ER+) tumors by screening a
tissue microarray of invasive breast cancer. We further investigated whether tumor progression in
these tumors is driven by the expression of GFRA1 and RET receptors or GDNF which is regulated
in response to the inflammatory microenvironment surrounding many epithelial cancers. In tumor
xenografts, they showed that the inflammatory cytokines tumor necrosis factor-α and interleukin-1β act
synergistically to up-regulate GDNF expression and this effect is mediated by a GDNF/GFRA1/RET
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axis [74]. Another research group found that circular GFRA1 RNA (circGFRA1) regulates GFRA1
expression through sponging miR-34a to exert regulatory functions in triple negative breast cancer
(TNBC) [75]. Their findings imply circGFRA1 may be a potential biomarker and/or therapeutic target
for TNBC. Our study showed that GFRA1 expression is regulated by nuclear factor kappa B (NFκB) in
pancreatic cancer. GDNF/GFRA1/RET signaling promotes cell proliferation and migration through
SRC and MMP signaling [40]. Unlike neuronal cells, GFRA1 overexpression induces tumor progression
in cancer cells. Collectively, the results from these investigations provide support to the idea that
GFRA1 may be applicable as a biomarker and/or therapeutic target for cancer. Further understanding
of GFRA1 expression will provide a major clue to solve the riddle of cell outcome, neuronal cell death
and cancer cell proliferation and survival.
Table 1. The expression of GDNF ligands and its receptors in cancer cells.
Type of Ligand

Type of Receptor

Biological Functions

Type of Cancer

References

ARTN
GDNF
GDNF
GDNF
ND
ND
ND
GDNF

GFRA1/GFRA3
RET/GFRA1
RET/GFRA1
RET/GFRA1
GFRA1
GFRA1
GFRA1
GFRA1

ND
ND
Oncogenicity
Aromatase inhibitor resistance
Cisplatin resistance by autophagy
ND
ND
Cell migration and proliferation

mammary carcinoma
Breast cancer
malignant melanoma
Breast cancer
Osteosarcoma
Breast cancer
Breast cancer
Pancreatic cancer

[76]
[74]
[77]
[78]
[73]
[79]
[75]
[40]

ARTN, artemin; GDNF, glial cell-line-derived neurotrophic factor; GFRA1, GDNF receptor alpha 1; GFRA3, GDNF
receptor alpha 3; RET, rearranged during transformation; ND, not determined.

5. Emerging Roles of GFRA1 in Chemoresistance
Although osteosarcoma is not a common cancer, it is a serious disease given that the most affected
age group are children and adolescents [80]. In addition, despite the fact that the long-term survival rate
has increased to approximately 70% thanks to the use of adjuvant therapy, about 10–20% of patients have
tumors which have already metastasized [81]. Indeed, it could be said that the success and draw-back
of chemotherapy is dependent on the resistance of cells to the drug used. To date, cisplatin is the most
widely used platinum-based anticancer drug for solid tumors [82]. It interacts with nucleophilic N7
sites of purine bases in DNA to induce DNA damage which leads to inhibition of tumor cell division
and initiation of apoptosis, or programmed cell death [83]. However, due to the resistance of cells to
cisplatin and drug toxicity, use of a combination therapy of methotrexate, doxorubicin and cisplatin has
become common practice. Chemoresistance can be caused by the failure of drug export, DNA repair
mechanisms, cancer stem cells, apoptotic signaling, or self-sufficiency for growth factor signaling [84].
Thus, understanding the mechanism of chemoresistance development may facilitate early detection,
diagnosis and prognosis, thereby making it essential to treat cancer more effectively.
Autophagy is known as a self-digest mechanism for recycling the unnecessary and dysfunctional
components to maintain homeostasis of cells [85,86]. At first, it was regarded as an alternative cell
death mechanism known as programmed cell death II [87–89]. However, recent paradoxical findings
demonstrated that autophagy also can play a role in cell survival against environmental stresses including
nutrient deficiency, chemotherapy, radiation, and hypoxia [87,88,90]. Currently, the roles of autophagy
in either apoptotic cell death as a tumor suppressive mechanism or cell survival mechanisms remain
mostly controversial. Moreover, the regulatory mechanism of autophagy in chemoresistance has rarely
been studied. Recently, our study demonstrated that GFRA1 induces autophagy as a novel regulatory
mechanism of osteosarcoma chemoresistance; although neither ligand nor GFRA1 coreceptor were
identified in this study, we found cisplatin triggers GFRA1 expression through NFκB [73]. The level of
GFRA1 expression was increased in two osteosarcoma cell lines, MG-63 and U-2 OS, following treatment
with cisplatin at both transcriptional and translational levels. However, two other chemotherapeutic
drugs that were used for osteosarcoma treatment, doxorubicin and methotrexate, did not induce GFRA1
expression, indicating that cisplatin specifically induces GFRA1 expression. However, we do not exclude
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the possibility that other chemotherapeutic drugs can also induce GFRA1 expression in other types
of cells as well as osteosarcoma cells. Previous studies have shown that NFκB upregulates GFRA1
mRNA expression through transcriptional activation [40]. Consistent with this finding, the levels
of NFκB and phosphorylated NFκB expression were increased in osteosarcoma cells after cisplatin
treatment compared to untreated cells. Inhibition of NFκB expression significantly reduced GFRA1
expression, suggesting that cisplatin-mediated activation of NFκB is one critical signaling pathway for
GFRA1 expression [73]. Knockdown of GFRA1 expression in osteosarcoma cells significantly increased
cisplatin-induced apoptosis, while overexpression of GFRA1 reduced cisplatin-induced apoptosis. Further
studies showed that cisplatin treatment significantly increased autophagy in osteosarcoma cells, whereas
it was not observed in GFRA1-deficient cells. GFRA1 overexpression in osteosarcoma cells significantly
increased cell proliferation in the presence or absence of cisplatin with increased autophagy compared
to control cells and this effect was blocked by the inhibition of autophagy. Src is one of the downstream
targets of GFRA1 signaling [9]. Mechanistic studies showed that Src phosphorylation was increased in
osteosarcoma cells with increased GFRA1 expression following cisplatin treatment and subsequently
increased AMP-activated protein kinase (AMPK) phosphorylation, which is involved in the regulation
of autophagy. Activated Src/AMPK signaling by GFRA1 increased the expression levels of beclin
1, high mobility group box 1 (HMGB1), and microtubule-associated protein light chain 3-II (LC3-II),
which are downstream molecules involved in autophagy, suggesting that cisplatin-induced GFRA1
vertically transferred its survival signal to autophagy molecules through the Src/AMPK pathway
(Figure 4). GDNF is the major ligand of GFRA1 as described above. However, GDNF had no effect
on osteosarcoma cell survival after cisplatin treatment. This result implies that cisplatin-mediated
activation of GFRA1 signaling is independent of GDNF. In addition, RET, a coreceptor of GDNF, was
not expressed in osteosarcoma cells [73]. Mouse xenograft studies showed that mice injected with
GFRA1-overexpressing osteosarcoma cells started to develop tumors 5 days after injection and produced
large-sized tumors (~90 mm3 ). In contrast, mice injected with control osteosarcoma cells did not develop
tumors until 17 days after injection and the resultant tumors were small (~10 mm3 ). Treatment of mice
with chloroquine, an autophagic inhibitor, in combination with cisplatin significantly reduced tumor
volume compared with PBS, chloroquine, or cisplatin-treated mice. Interestingly, we found that four out
of nine osteosarcoma patients whose tumors were metastasized to the lung were positive for both GFRA1
and HMGB1 expression. These results showed that GFRA1-mediated autophagy is associated with cancer
cell survival/tumor progression in patients that did not respond to cisplatin treatment [73]. In summary,
our data showed that GFRA1 plays a critical role in cisplatin-induced chemoresistance via autophagy and
it suggests that GFRA1 may be a potential therapeutic target against chemoresistance.

Figure 4. Schematic diagram for autophagy mediated by GFRA1 in cisplatin-resistant osteosarcoma.
Cisplatin induces GFRA1 through NFκB, and GFRA1 activates autophagy by SRC/AMPK signaling.
Finally, GFRA1-mediated autophagy inhibits cisplatin-induced apoptosis, resulting in cell proliferation
and migration.
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6. Conclusions
Although studies of GDNF family ligands and their receptors reveal that they are emerging
targets for neuronal disease and cancer therapy, the complexity of their signaling still remains
unclear. GFLs and GFRA1 expression levels may be dependent on their specific roles in cells.
In addition, the choice between GDNF ligand family and GFRA1 also may determine their function.
In other words, because cell-to-cell interaction is required for the communication of neuronal cells,
GDNF/GFRA1 levels may be increased. Definitely, the discovery of sGFRA provides a clue as to how
GDNF ligands and co-receptors can physiologically interact at a distance. The loss of GDNF/GFRA1
in the neuron inhibits its development, such as synapse formation in neuronal cells. Similarly,
aberrant expression of GFRA1 has been often observed in cancer. Furthermore, GFRA1 expression is
elevated by cisplatin treatment in osteosarcoma cells. GFRA1-mediated signaling activated autophagy,
resulting in hyperproliferation, cell survival and metastasis in osteosarcoma. Taken together, a further
understanding of the mechanisms involving GFRA1 may provide critical information towards
discovering novel potential therapeutic approaches for overcoming chemoresistance in osteosarcoma.
Acknowledgments: This work was supported, in part, by National Institutes of Environmental Health Sciences
Grant ES022250 (to Dae Joon Kim).
Conflicts of Interest: The authors declare no conflict of interest.

References
1.

2.

3.

4.

5.

6.

7.

8.
9.
10.
11.

Jing, S.; Wen, D.; Yu, Y.; Holst, P.L.; Luo, Y.; Fang, M.; Tamir, R.; Antonio, L.; Hu, Z.; Cupples, R.; et al.
GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for
GDNF. Cell 1996, 85, 1113–1124. [CrossRef]
Treanor, J.J.; Goodman, L.; de Sauvage, F.; Stone, D.M.; Poulsen, K.T.; Beck, C.D.; Gray, C.; Armanini, M.P.;
Pollock, R.A.; Hefti, F.; et al. Characterization of a multicomponent receptor for GDNF. Nature 1996, 382,
80–83. [CrossRef] [PubMed]
Baloh, R.H.; Tansey, M.G.; Golden, J.P.; Creedon, D.J.; Heuckeroth, R.O.; Keck, C.L.; Zimonjic, D.B.;
Popescu, N.C.; Johnson, E.M., Jr.; Milbrandt, J. TRNR2, a novel receptor that mediates neurturin and
GDNF signaling through Ret. Neuron 1997, 18, 793–802. [CrossRef]
Baloh, R.H.; Gorodinsky, A.; Golden, J.P.; Tansey, M.G.; Keck, C.L.; Popescu, N.C.; Johnson, E.M., Jr.;
Milbrandt, J. GFRα3 is an orphan member of the GDNF/neurturin/persephin receptor family. Proc. Natl.
Acad. Sci. USA 1998, 95, 5801–5806. [CrossRef] [PubMed]
Baloh, R.H.; Tansey, M.G.; Lampe, P.A.; Fahrner, T.J.; Enomoto, H.; Simburger, K.S.; Leitner, M.L.; Araki, T.;
Johnson, E.M., Jr.; Milbrandt, J. Artemin, a novel member of the GDNF ligand family, supports peripheral
and central neurons and signals through the GFRα3-RET receptor complex. Neuron 1998, 21, 1291–1302.
[CrossRef]
Naveilhan, P.; Baudet, C.; Mikaels, A.; Shen, L.; Westphal, H.; Ernfors, P. Expression and regulation of GFRα3,
a glial cell line-derived neurotrophic factor family receptor. Proc. Natl. Acad. Sci. USA 1998, 95, 1295–1300.
[CrossRef] [PubMed]
Enokido, Y.; de Sauvage, F.; Hongo, J.A.; Ninkina, N.; Rosenthal, A.; Buchman, V.L.; Davies, A.M. GFRα-4
and the tyrosine kinase Ret form a functional receptor complex for persephin. Curr. Biol. 1998, 8, 1019–1022.
[CrossRef]
Lin, L.F.; Doherty, D.H.; Lile, J.D.; Bektesh, S.; Collins, F. GDNF: A glial cell line-derived neurotrophic factor
for midbrain dopaminergic neurons. Science 1993, 260, 1130–1132. [CrossRef] [PubMed]
Airaksinen, M.S.; Saarma, M. The GDNF family: Signalling, biological functions and therapeutic value.
Nat. Rev. Neurosci. 2002, 3, 383–394. [CrossRef] [PubMed]
Ibanez, C.F.; Andressoo, J.O. Biology of GDNF and its receptors—Relevance for disorders of the central
nervous system. Neurobiol. Dis. 2017, 97, 80–89. [CrossRef] [PubMed]
Ibanez, C.F. Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb Perspect. Biol.
2013, 5. [CrossRef] [PubMed]

Int. J. Mol. Sci. 2018, 19, 1078

12.

13.
14.
15.
16.
17.

18.

19.
20.

21.

22.
23.
24.
25.
26.

27.
28.

29.

30.

31.
32.

11 of 14

Trupp, M.; Arenas, E.; Fainzilber, M.; Nilsson, A.S.; Sieber, B.A.; Grigoriou, M.; Kilkenny, C.; Salazar-Grueso, E.;
Pachnis, V.; Arumae, U. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996, 381,
785–789. [CrossRef] [PubMed]
Saarma, M. GDNF—A stranger in the TGF-β superfamily? Eur. J. Biochem. 2000, 267, 6968–6971. [CrossRef]
[PubMed]
Sariola, H.; Saarma, M. Novel functions and signalling pathways for GDNF. J. Cell Sci. 2003, 116, 3855–3862.
[CrossRef] [PubMed]
Santoro, M.; Melillo, R.M.; Carlomagno, F.; Vecchio, G.; Fusco, A. Minireview: RET: Normal and abnormal
functions. Endocrinology 2004, 145, 5448–5451. [CrossRef] [PubMed]
Paratcha, G.; Ledda, F.; Ibanez, C.F. The neural cell adhesion molecule NCAM is an alternative signaling
receptor for GDNF family ligands. Cell 2003, 113, 867–879. [CrossRef]
Meng, X.; Lindahl, M.; Hyvonen, M.E.; Parvinen, M.; de Rooij, D.G.; Hess, M.W.; Raatikainen-Ahokas, A.;
Sainio, K.; Rauvala, H.; Lakso, M.; et al. Regulation of cell fate decision of undifferentiated spermatogonia
by GDNF. Science 2000, 287, 1489–1493. [CrossRef] [PubMed]
Viglietto, G.; Dolci, S.; Bruni, P.; Baldassarre, G.; Chiariotti, L.; Melillo, R.M.; Salvatore, G.; Chiappetta, G.;
Sferratore, F.; Fusco, A.; et al. Glial cell line-derived neutrotrophic factor and neurturin can act as paracrine
growth factors stimulating DNA synthesis of Ret-expressing spermatogonia. Int. J. Oncol. 2000, 16, 689–694.
[CrossRef] [PubMed]
Costantini, F.; Shakya, R. GDNF/Ret signaling and the development of the kidney. Bioessays 2006, 28,
117–127. [CrossRef] [PubMed]
Besset, V.; Scott, R.P.; Ibanez, C.F. Signaling complexes and protein-protein interactions involved in the
activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
J. Biol. Chem. 2000, 275, 39159–39166. [CrossRef] [PubMed]
Paratcha, G.; Ledda, F.; Baars, L.; Coulpier, M.; Besset, V.; Anders, J.; Scott, R.; Ibanez, C.F. Released
GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism
of recruitment of c-Ret to lipid rafts. Neuron 2001, 29, 171–184. [CrossRef]
Ledda, F.; Paratcha, G.; Ibanez, C.F. Target-derived GFRalpha1 as an attractive guidance signal for developing
sensory and sympathetic axons via activation of Cdk5. Neuron 2002, 36, 387–401. [CrossRef]
Grumet, M.; Rutishauser, U.; Edelman, G.M. Neural cell adhesion molecule is on embryonic muscle cells
and mediates adhesion to nerve cells in vitro. Nature 1982, 295, 693–695. [CrossRef] [PubMed]
Covault, J.; Sanes, J.R. Neural cell adhesion molecule (N-CAM) accumulates in denervated and paralyzed
skeletal muscles. Proc. Natl. Acad. Sci. USA 1985, 82, 4544–4548. [CrossRef] [PubMed]
Thiery, J.P.; Duband, J.L.; Rutishauser, U.; Edelman, G.M. Cell adhesion molecules in early chicken
embryogenesis. Proc. Natl. Acad. Sci. USA 1982, 79, 6737–6741. [CrossRef] [PubMed]
Rutishauser, U.; Thiery, J.P.; Brackenbury, R.; Edelman, G.M. Adhesion among neural cells of the chick
embryo. III. Relationship of the surface molecule CAM to cell adhesion and the development of histotypic
patterns. J. Cell Biol. 1978, 79, 371–381. [CrossRef] [PubMed]
Noble, M.; Albrechtsen, M.; Moller, C.; Lyles, J.; Bock, E.; Goridis, C.; Watanabe, M.; Rutishauser, U. Glial cells
express N-CAM/D2-CAM-like polypeptides in vitro. Nature 1985, 316, 725–728. [CrossRef] [PubMed]
Pollerberg, E.G.; Sadoul, R.; Goridis, C.; Schachner, M. Selective expression of the 180-kD component of the
neural cell adhesion molecule N-CAM during development. J. Cell Biol. 1985, 101, 1921–1929. [CrossRef]
[PubMed]
Van Acker, H.H.; Anguille, S.; Willemen, Y.; Van den Bergh, J.M.; Berneman, Z.N.; Lion, E.; Smits, E.L.;
Van Tendeloo, V.F. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector
functions of human gamma delta T cells. J. Hematol. Oncol. 2016, 9, 101. [CrossRef] [PubMed]
Kelly-Rogers, J.; Madrigal-Estebas, L.; O’Connor, T.; Doherty, D.G. Activation-induced expression of CD56
by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro.
Hum. Immunol. 2006, 67, 863–873. [CrossRef] [PubMed]
Roothans, D.; Smits, E.; Lion, E.; Tel, J.; Anguille, S. CD56 marks human dendritic cell subsets with cytotoxic
potential. Oncoimmunology 2013, 2, e23037. [CrossRef] [PubMed]
Reyes, A.A.; Small, S.J.; Akeson, R. At least 27 alternatively spliced forms of the neural cell adhesion
molecule mRNA are expressed during rat heart development. Mol. Cell. Biol. 1991, 11, 1654–1661. [CrossRef]
[PubMed]

Int. J. Mol. Sci. 2018, 19, 1078

33.

34.

35.
36.

37.
38.

39.

40.

41.

42.
43.

44.

45.

46.
47.

48.
49.

50.

51.

12 of 14

Wang, C.Y.; Yang, F.; He, X.P.; Je, H.S.; Zhou, J.Z.; Eckermann, K.; Kawamura, D.; Feng, L.; Shen, L.;
Lu, B. Regulation of neuromuscular synapse development by glial cell line-derived neurotrophic factor and
neurturin. J. Biol. Chem. 2002, 277, 10614–10625. [CrossRef] [PubMed]
Nielsen, J.; Gotfryd, K.; Li, S.; Kulahin, N.; Soroka, V.; Rasmussen, K.K.; Bock, E.; Berezin, V. Role of glial cell
line-derived neurotrophic factor (GDNF)-neural cell adhesion molecule (NCAM) interactions in induction of
neurite outgrowth and identification of a binding site for NCAM in the heel region of GDNF. J. Neurosci.
2009, 29, 11360–11376. [CrossRef] [PubMed]
Ledda, F. Ligand-induced cell adhesion as a new mechanism to promote synapse formation. Cell Adhes. Migr.
2007, 1, 137–139. [CrossRef]
Glerup, S.; Lume, M.; Olsen, D.; Nyengaard, J.R.; Vaegter, C.B.; Gustafsen, C.; Christensen, E.I.; Kjolby, M.;
Hay-Schmidt, A.; Bender, D.; et al. SorLA controls neurotrophic activity by sorting of GDNF and its receptors
GFRα1 and RET. Cell Rep. 2013, 3, 186–199. [CrossRef] [PubMed]
Arenas, E.; Trupp, M.; Akerud, P.; Ibanez, C.F. GDNF prevents degeneration and promotes the phenotype of
brain noradrenergic neurons in vivo. Neuron 1995, 15, 1465–1473. [CrossRef]
Gill, S.S.; Patel, N.K.; Hotton, G.R.; O’Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J.; Svendsen, C.N.;
Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med.
2003, 9, 589–595. [CrossRef] [PubMed]
Lang, A.E.; Gill, S.; Patel, N.K.; Lozano, A.; Nutt, J.G.; Penn, R.; Brooks, D.J.; Hotton, G.; Moro, E.; Heywood, P.;
et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in
Parkinson disease. Ann. Neurol. 2006, 59, 459–466. [CrossRef] [PubMed]
Kim, M.H.; Kim, H.B.; Acharya, S.; Sohn, H.M.; Jun, J.Y.; Chang, I.Y.; You, H.J. Ape1/Ref-1 induces glial
cell-derived neurotropic factor (GDNF) responsiveness by upregulating GDNF receptor alpha1 expression.
Mol. Cell. Biol. 2009, 29, 2264–2277. [CrossRef] [PubMed]
Kang, M.Y.; Kim, K.Y.; Yoon, Y.; Kang, Y.; Kim, H.B.; Youn, C.K.; Kim, D.H.; Kim, M.H. Ape1/Ref-1
Stimulates GDNF/GFRα1-mediated Downstream Signaling and Neuroblastoma Proliferation. Korean J.
Physiol. Pharmacol. 2009, 13, 349–356. [CrossRef] [PubMed]
Newgreen, D.; Young, H.M. Enteric nervous system: Development and developmental disturbances—Part 2.
Pediatr. Dev. Pathol. 2002, 5, 329–349. [CrossRef] [PubMed]
Shen, L.; Pichel, J.G.; Mayeli, T.; Sariola, H.; Lu, B.; Westphal, H. Gdnf haploinsufficiency causes
Hirschsprung-like intestinal obstruction and early-onset lethality in mice. Am. J. Hum. Genet. 2002, 70,
435–447. [CrossRef] [PubMed]
Borghini, S.; Bocciardi, R.; Bonardi, G.; Matera, I.; Santamaria, G.; Ravazzolo, R.; Ceccherini, I. Hirschsprung
associated GDNF mutations do not prevent RET activation. Eur. J. Hum. Genet. 2002, 10, 183–187. [CrossRef]
[PubMed]
Borrego, S.; Fernandez, R.M.; Dziema, H.; Niess, A.; Lopez-Alonso, M.; Antinolo, G.; Eng, C. Investigation
of germline GFRA4 mutations and evaluation of the involvement of GFRA1, GFRA2, GFRA3, and GFRA4
sequence variants in Hirschsprung disease. J. Med. Genet. 2003, 40, e18. [CrossRef] [PubMed]
Eketjall, S.; Ibanez, C.F. Functional characterization of mutations in the GDNF gene of patients with
Hirschsprung disease. Hum. Mol. Genet. 2002, 11, 325–329. [CrossRef] [PubMed]
Bespalov, M.M.; Sidorova, Y.A.; Tumova, S.; Ahonen-Bishopp, A.; Magalhaes, A.C.; Kulesskiy, E.; Paveliev, M.;
Rivera, C.; Rauvala, H.; Saarma, M. Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF,
neurturin, and artemin. J. Cell Biol. 2011, 192, 153–169. [CrossRef] [PubMed]
Pozas, E.; Ibanez, C.F. GDNF and GFRalpha1 promote differentiation and tangential migration of cortical
GABAergic neurons. Neuron 2005, 45, 701–713. [CrossRef] [PubMed]
Perrinjaquet, M.; Sjostrand, D.; Moliner, A.; Zechel, S.; Lamballe, F.; Maina, F.; Ibanez, C.F. MET signaling
in GABAergic neuronal precursors of the medial ganglionic eminence restricts GDNF activity in cells that
express GFRα1 and a new transmembrane receptor partner. J. Cell Sci. 2011, 124, 2797–2805. [CrossRef]
[PubMed]
Charoy, C.; Nawabi, H.; Reynaud, F.; Derrington, E.; Bozon, M.; Wright, K.; Falk, J.; Helmbacher, F.;
Kindbeiter, K.; Castellani, V. gdnf activates midline repulsion by Semaphorin3B via NCAM during
commissural axon guidance. Neuron 2012, 75, 1051–1066. [CrossRef] [PubMed]
Duveau, V.; Fritschy, J.M. PSA-NCAM-dependent GDNF signaling limits neurodegeneration and
epileptogenesis in temporal lobe epilepsy. Eur. J. Neurosci. 2010, 32, 89–98. [CrossRef] [PubMed]

Int. J. Mol. Sci. 2018, 19, 1078

52.

53.
54.
55.

56.

57.

58.
59.

60.

61.
62.
63.
64.

65.
66.

67.

68.

69.

70.
71.

13 of 14

Euteneuer, S.; Yang, K.H.; Chavez, E.; Leichtle, A.; Loers, G.; Olshansky, A.; Pak, K.; Schachner, M.; Ryan, A.F.
Glial cell line-derived neurotrophic factor (GDNF) induces neuritogenesis in the cochlear spiral ganglion via
neural cell adhesion molecule (NCAM). Mol. Cell. Neurosci. 2013, 54, 30–43. [CrossRef] [PubMed]
Paratcha, G.; Ledda, F. GDNF and GFRalpha: A versatile molecular complex for developing neurons. Trends
Neurosci. 2008, 31, 384–391. [CrossRef] [PubMed]
Paratcha, G.; Ibanez, C.F. Lipid rafts and the control of neurotrophic factor signaling in the nervous system:
Variations on a theme. Curr. Opin. Neurobiol. 2002, 12, 542–549. [CrossRef]
Krakora, D.; Mulcrone, P.; Meyer, M.; Lewis, C.; Bernau, K.; Gowing, G.; Zimprich, C.; Aebischer, P.;
Svendsen, C.N.; Suzuki, M. Synergistic effects of GDNF and VEGF on lifespan and disease progression in a
familial ALS rat model. Mol. Ther. 2013, 21, 1602–1610. [CrossRef] [PubMed]
Meissner, W.G.; Frasier, M.; Gasser, T.; Goetz, C.G.; Lozano, A.; Piccini, P.; Obeso, J.A.; Rascol, O.; Schapira, A.;
Voon, V.; et al. Priorities in Parkinson’s disease research. Nat. Rev. Drug Discov. 2011, 10, 377–393. [CrossRef]
[PubMed]
Trupp, M.; Belluardo, N.; Funakoshi, H.; Ibanez, C.F. Complementary and overlapping expression of glial
cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates
multiple mechanisms of trophic actions in the adult rat CNS. J. Neurosci. 1997, 17, 3554–3567. [CrossRef]
[PubMed]
Burke, R.E.; O’Malley, K. Axon degeneration in Parkinson’s disease. Exp. Neurol. 2013, 246, 72–83. [CrossRef]
[PubMed]
Kholodilov, N.; Kim, S.R.; Yarygina, O.; Kareva, T.; Cho, J.W.; Baohan, A.; Burke, R.E. Glial cell line-derived
neurotrophic factor receptor-α1 expressed in striatum in trans regulates development and injury response of
dopamine neurons of the substantia nigra. J. Neurochem. 2011, 116, 486–498. [CrossRef] [PubMed]
Pruett, B.S.; Salvatore, M.F. Nigral GFRalpha1 infusion in aged rats increases locomotor activity, nigral
tyrosine hydroxylase, and dopamine content in synchronicity. Mol. Neurobiol. 2013, 47, 988–999. [CrossRef]
[PubMed]
Ledda, F.; Paratcha, G.; Sandoval-Guzman, T.; Ibanez, C.F. GDNF and GFRα1 promote formation of neuronal
synapses by ligand-induced cell adhesion. Nat. Neurosci. 2007, 10, 293–300. [CrossRef] [PubMed]
Marks, C.; Belluscio, L.; Ibanez, C.F. Critical role of GFRalpha1 in the development and function of the main
olfactory system. J. Neurosci. 2012, 32, 17306–17320. [CrossRef] [PubMed]
Duarte, E.P.; Curcio, M.; Canzoniero, L.M.; Duarte, C.B. Neuroprotection by GDNF in the ischemic brain.
Growth Factors 2012, 30, 242–257. [CrossRef] [PubMed]
Reeben, M.; Laurikainen, A.; Hiltunen, J.O.; Castren, E.; Saarma, M. The messenger RNAs for both glial cell
line-derived neurotrophic factor receptors, c-ret and GDNFRalpha, are induced in the rat brain in response
to kainate-induced excitation. Neuroscience 1998, 83, 151–159. [CrossRef]
Scholz, D.; Chernyshova, Y.; Leist, M. Control of Aβ release from human neurons by differentiation status
and RET signaling. Neurobiol. Aging 2013, 34, 184–199. [CrossRef] [PubMed]
Ray, S.; Britschgi, M.; Herbert, C.; Takeda-Uchimura, Y.; Boxer, A.; Blennow, K.; Friedman, L.F.; Galasko, D.R.;
Jutel, M.; Karydas, A.; et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma
signaling proteins. Nat. Med. 2007, 13, 1359–1362. [CrossRef] [PubMed]
Messer, C.J.; Eisch, A.J.; Carlezon, W.A., Jr.; Whisler, K.; Shen, L.; Wolf, D.H.; Westphal, H.; Collins, F.;
Russell, D.S.; Nestler, E.J. Role for GDNF in biochemical and behavioral adaptations to drugs of abuse.
Neuron 2000, 26, 247–257. [CrossRef]
Ubhi, K.; Inglis, C.; Mante, M.; Patrick, C.; Adame, A.; Spencer, B.; Rockenstein, E.; May, V.; Winkler, J.;
Masliah, E. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of
α-synucleinopathy. Exp. Neurol. 2012, 234, 405–416. [CrossRef] [PubMed]
Tunca, Z.; Kivircik Akdede, B.; Ozerdem, A.; Alkin, T.; Polat, S.; Ceylan, D.; Bayin, M.; Cengizcetin Kocuk, N.;
Simsek, S.; Resmi, H.; et al. Diverse glial cell line-derived neurotrophic factor (GDNF) support between
mania and schizophrenia: A comparative study in four major psychiatric disorders. Eur. Psychiatry 2015, 30,
198–204. [CrossRef] [PubMed]
Fontenelle, L.F.; Barbosa, I.G.; Luna, J.V.; Rocha, N.P.; Silva Miranda, A.; Teixeira, A.L. Neurotrophic factors
in obsessive-compulsive disorder. Psychiatry Res. 2012, 199, 195–200. [CrossRef] [PubMed]
Moises, H.W.; Zoega, T.; Gottesman, I.I. The glial growth factors deficiency and synaptic destabilization
hypothesis of schizophrenia. BMC Psychiatry 2002, 2, 8. [CrossRef]

Int. J. Mol. Sci. 2018, 19, 1078

72.

73.

74.

75.

76.

77.

78.

79.

80.
81.
82.

83.
84.

85.
86.
87.
88.
89.
90.

14 of 14

Maheu, M.; Lopez, J.P.; Crapper, L.; Davoli, M.A.; Turecki, G.; Mechawar, N. MicroRNA regulation of central
glial cell line-derived neurotrophic factor (GDNF) signalling in depression. Transl. Psychiatry 2015, 5, e511.
[CrossRef] [PubMed]
Kim, M.; Jung, J.Y.; Choi, S.; Lee, H.; Morales, L.D.; Koh, J.T.; Kim, S.H.; Choi, Y.D.; Choi, C.; Slaga, T.J.; et al.
GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy. Autophagy
2017, 13, 149–168. [CrossRef] [PubMed]
Esseghir, S.; Todd, S.K.; Hunt, T.; Poulsom, R.; Plaza-Menacho, I.; Reis-Filho, J.S.; Isacke, C.M. A role for glial
cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFRα1 receptor
up-regulation in breast cancer. Cancer Res. 2007, 67, 11732–11741. [CrossRef] [PubMed]
He, R.; Liu, P.; Xie, X.; Zhou, Y.; Liao, Q.; Xiong, W.; Li, X.; Li, G.; Zeng, Z.; Tang, H. circGFRA1 and GFRA1
act as ceRNAs in triple negative breast cancer by regulating miR-34a. J. Exp. Clin. Cancer Res. 2017, 36, 145.
[CrossRef] [PubMed]
Wu, Z.S.; Pandey, V.; Wu, W.Y.; Ye, S.; Zhu, T.; Lobie, P.E. Prognostic significance of the expression of GFRα1,
GFRalpha3 and syndecan-3, proteins binding ARTEMIN, in mammary carcinoma. BMC Cancer 2013, 13, 34.
[CrossRef] [PubMed]
Ohshima, Y.; Yajima, I.; Takeda, K.; Iida, M.; Kumasaka, M.; Matsumoto, Y.; Kato, M. c-RET molecule in malignant
melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PLoS ONE 2010, 5, e10279.
[CrossRef] [PubMed]
Morandi, A.; Martin, L.A.; Gao, Q.; Pancholi, S.; Mackay, A.; Robertson, D.; Zvelebil, M.; Dowsett, M.;
Plaza-Menacho, I.; Isacke, C.M. GDNF-RET signaling in ER-positive breast cancers is a key determinant of
response and resistance to aromatase inhibitors. Cancer Res. 2013, 73, 3783–3795. [CrossRef] [PubMed]
Bhakta, S.; Crocker, L.M.; Chen, Y.; Hazen, M.; Schutten, M.M.; Li, D.; Kuijl, C.; Ohri, R.; Zhong, F.; Poon, K.A.;
et al. An anti-GDNF Family Receptor α 1(GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone
Receptor-Positive Breast Cancer. Mol. Cancer Ther. 2018, 17, 638–649. [CrossRef] [PubMed]
Ottaviani, G.; Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat. Res. 2009, 152, 3–13. [PubMed]
Luetke, A.; Meyers, P.A.; Lewis, I.; Juergens, H. Osteosarcoma treatment—Where do we stand? A state of
the art review. Cancer Treat. Rev. 2014, 40, 523–532. [CrossRef] [PubMed]
Meyers, P.A.; Schwartz, C.L.; Krailo, M.; Kleinerman, E.S.; Betcher, D.; Bernstein, M.L.; Conrad, E.;
Ferguson, W.; Gebhardt, M.; Goorin, A.M.; et al. Osteosarcoma: A randomized, prospective trial of the
addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
J. Clin. Oncol. 2005, 23, 2004–2011. [CrossRef] [PubMed]
Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol.
2014, 740, 364–378. [CrossRef] [PubMed]
Sui, X.; Chen, R.; Wang, Z.; Huang, Z.; Kong, N.; Zhang, M.; Han, W.; Lou, F.; Yang, J.; Zhang, Q.; et al.
Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death Dis.
2013, 4, e838. [CrossRef] [PubMed]
Lum, J.J.; DeBerardinis, R.J.; Thompson, C.B. Autophagy in metazoans: Cell survival in the land of plenty.
Nat. Rev. Mol. Cell. Biol. 2005, 6, 439–448. [CrossRef] [PubMed]
Boya, P.; Reggiori, F.; Codogno, P. Emerging regulation and functions of autophagy. Nat. Cell Biol. 2013, 15,
713–720. [CrossRef] [PubMed]
Kondo, Y.; Kanzawa, T.; Sawaya, R.; Kondo, S. The role of autophagy in cancer development and response to
therapy. Nat. Rev. Cancer 2005, 5, 726–734. [CrossRef] [PubMed]
Levine, B. Unraveling the role of autophagy in cancer. Autophagy 2006, 2, 65–66. [CrossRef] [PubMed]
Mathew, R.; Karantza-Wadsworth, V.; White, E. Role of autophagy in cancer. Nat. Rev. Cancer 2007, 7,
961–967. [CrossRef] [PubMed]
Chen, N.; Karantza-Wadsworth, V. Role and regulation of autophagy in cancer. Biochim. Biophys. Acta 2009, 1793,
1516–1523. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

